Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of acute myelogenous leukemia (AML) provides the essential foundation for patients, families, and healthcare professionals seeking clear information about this aggressive blood cancer. AML originates in the bone marrow, where abnormal myeloid cells proliferate rapidly, displacing normal blood‑forming cells. Each year, roughly 20,000 new cases are diagnosed worldwide, and the disease accounts for about 1% of all cancers, underscoring the importance of timely understanding and intervention.
This page is designed for international patients who are considering evaluation or treatment at Liv Hospital, a JCI‑accredited center in Istanbul that offers comprehensive hematology services. We will explore the disease’s biology, risk factors, clinical presentation, diagnostic pathways, and the latest therapeutic options, helping you navigate the complex journey from diagnosis to recovery.
By presenting a thorough overview and definition of AML, we aim to empower you with knowledge that supports informed decisions and confidence when collaborating with our multidisciplinary medical team.
Acute myelogenous leukemia is a malignant disorder of the myeloid line of blood cells. In a healthy bone marrow, stem cells mature into functional red cells, white cells, and platelets. In AML, genetic mutations cause these progenitor cells to become leukemic blasts that fail to mature, leading to bone‑marrow failure and impaired immunity.
The disease is classified based on the French‑American‑British (FAB) system and the World Health Organization (WHO) criteria, which identify subtypes such as:
Understanding the specific subtype is critical because it influences treatment choices and prognosis. For example, APL (M3) responds exceptionally well to all‑trans retinoic acid (ATRA) combined with arsenic trioxide, achieving remission rates above 90%.
The overview and definition of AML also emphasizes its rapid progression. Unlike chronic leukemias, AML evolves over weeks to months, demanding prompt medical attention to prevent life‑threatening complications such as severe anemia, infections, and bleeding.
While the exact cause of AML remains unclear, several risk factors increase the likelihood of developing the disease. Most cases arise from acquired genetic mutations, but inherited predispositions also play a role.
In addition to environmental and lifestyle factors, specific molecular abnormalities such as FLT3‑ITD, NPM1, and CEBPA mutations are detected in a large proportion of AML patients. These mutations not only drive disease development but also serve as therapeutic targets, enabling personalized treatment strategies.
Recognizing these risk elements forms part of a comprehensive overview and definition that helps clinicians assess individual patient risk and tailor preventive counseling when appropriate.
Because AML disrupts normal blood cell production, its clinical manifestations reflect deficiencies across the three major blood components. Common presenting features include:
Laboratory evaluation typically reveals a high white‑blood‑cell count with circulating blasts, low hemoglobin, and reduced platelet numbers. Occasionally, patients present with leukostasis—a dangerous condition where extremely high blast counts cause vascular obstruction, leading to respiratory distress or neurological deficits.
Understanding these signs is essential for early detection. The overview and definition of AML emphasizes that any unexplained combination of anemia, infections, and bleeding warrants immediate hematologic assessment, especially in individuals with known risk factors.
Accurate diagnosis of AML relies on a systematic approach that integrates morphologic, immunophenotypic, cytogenetic, and molecular data. The core steps include:
td>Define lineage and maturation stage
Therapeutic management of AML is multimodal, aiming to achieve complete remission (CR) and prevent relapse. The main treatment pillars are:
Recent advances have improved overall survival, especially for younger patients and those receiving targeted therapies. Five‑year survival rates now range from 30% for adverse‑risk disease to over 70% for favorable‑risk AML.
Liv Hospital’s hematology department integrates these evidence‑based protocols with state‑of‑the‑art facilities, including a dedicated bone‑marrow transplant unit and access to clinical trials exploring novel immunotherapies such as CAR‑T cells for AML.
In the context of a comprehensive overview and definition, it is essential to recognize that treatment decisions are individualized, taking into account age, performance status, genetic risk, and patient preferences.
Liv Hospital combines JCI accreditation, a multidisciplinary oncology team, and a patient‑centered approach designed for international visitors. Our hematology unit offers cutting‑edge diagnostics, personalized treatment plans, and seamless coordination of travel, accommodation, and interpreter services. With a focus on safety, quality, and cultural sensitivity, we strive to make complex AML care as comfortable and effective as possible for patients from around the globe.
Take the first step toward expert AML care. Contact Liv Hospital today to schedule a virtual consultation, and let our specialists guide you through every stage of treatment and recovery.
Send us all your questions or requests, and our expert team will assist you.
AML arises when genetic mutations cause myeloid progenitor cells to become leukemic blasts that fail to mature into functional blood cells. These blasts proliferate rapidly, crowding out normal red cells, white cells, and platelets, which leads to anemia, infections, and bleeding. The disease can develop over weeks to months, making early detection crucial. Diagnosis requires a combination of blood tests, bone‑marrow biopsy, flow cytometry, and molecular studies. Treatment aims to achieve complete remission and prevent relapse, often using intensive chemotherapy and targeted agents. Prognosis depends on patient age, performance status, and specific genetic abnormalities.
The FAB classification includes M0 (minimally differentiated) through M7 (megakaryoblastic), while WHO adds cytogenetic and molecular criteria. Subtype identification is essential because it guides therapeutic choices; for example, acute promyelocytic leukemia (M3) responds dramatically to all‑trans retinoic acid (ATRA) plus arsenic trioxide, achieving remission rates above 90%. Other subtypes may require different induction regimens or benefit from specific targeted drugs like FLT3 inhibitors for FLT3‑ITD positive disease. Risk stratification (favorable, intermediate, adverse) incorporates these subtypes and influences decisions about consolidation therapy, including allogeneic stem‑cell transplantation. Understanding the subtype also provides prognostic information for patients and clinicians.
Most AML cases are linked to acquired genetic mutations, but several environmental and hereditary factors raise risk. Survivors of other cancers who received high‑dose chemotherapy or radiation have a higher incidence of secondary AML due to DNA damage. Occupational exposure to benzene or formaldehyde disrupts normal hematopoiesis and can trigger leukemogenesis. Inherited conditions such as Down syndrome, Fanconi anemia, and other DNA‑repair disorders predispose individuals to AML. Lifestyle factors like smoking introduce carcinogenic compounds that increase mutation burden. Age is a strong predictor, with incidence sharply rising after 60 years, reflecting cumulative genetic insults over a lifetime.
Because AML replaces normal blood‑forming cells, patients often present with anemia (fatigue, pallor, shortness of breath), thrombocytopenia (easy bruising, petechiae, prolonged bleeding), and neutropenia (recurrent infections, fever, oral ulcers). Bone pain, especially in the ribs, pelvis, or long bones, may occur due to marrow expansion. An enlarged spleen or liver can cause abdominal fullness or discomfort. Systemic signs such as unexplained weight loss and night sweats are also frequent. Laboratory tests typically reveal a high white‑blood‑cell count with circulating blasts, low hemoglobin, and low platelets. In severe cases, leukostasis can cause respiratory distress or neurological deficits, requiring urgent intervention.
The diagnostic work‑up starts with a complete blood count and differential to detect blasts and cytopenias, followed by a peripheral blood smear for morphological assessment. Definitive confirmation requires a bone‑marrow aspiration and biopsy, with ≥20 % blasts meeting WHO criteria. Flow cytometry defines the immunophenotype, distinguishing AML from other leukemias. Cytogenetic analysis (karyotyping, FISH) identifies chromosomal abnormalities such as t(8;21) or inv(16), while next‑generation sequencing detects mutations like FLT3‑ITD, NPM1, or CEBPA. Unlike solid tumors, AML does not have a traditional stage; instead, patients are stratified into favorable, intermediate, or adverse risk groups based on cytogenetic and molecular findings, which guide treatment intensity and transplant decisions.
The standard induction regimen is the “7+3” protocol—seven days of cytarabine plus three days of an anthracycline—to achieve complete remission. Consolidation may involve additional chemotherapy cycles or allogeneic hematopoietic stem‑cell transplantation for high‑risk patients. Targeted therapies have expanded options: FLT3 inhibitors (midostaurin, gilteritinib) for FLT3‑mutated disease, IDH1/2 inhibitors (ivosidenib, enasidenib) for IDH‑mutated AML, and the BCL‑2 inhibitor venetoclax, often combined with hypomethylating agents. Supportive care includes transfusion support, antimicrobial prophylaxis, and management of tumor‑lysis syndrome. Recent advances, including clinical trials of CAR‑T cell therapy, are improving survival, especially for younger patients and those with favorable genetics. Treatment decisions are individualized based on age, performance status, genetic risk, and patient preferences.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
